Banking on robust above-market growth across all business units, BSX is expected to have witnessed strong international momentum in the first quarter.

Boston Scientific will face more benign competition than previously feared when it comes to pulsed field ablation, according ...

Holston Valley Medical Center is the first hospital in East Tennessee, Southwest Virginia and Southeast Kentucky to offer ...

RBC Capital is still sweet on Boston Scientific, holding firm on its $116 price target and an Outperform rating. The analyst ...

We came across a bullish thesis on Boston Scientific Corporation (BSX) on Substack by Magnus Ofstad. In this article, we will ...

Truist lowered the firm’s price target on Boston Scientific (BSX) to $113 from $120 and keeps a Buy rating on the shares as part of a broad ...

Despite a shaky quarter due to U.S.-China trade tensions and a 6% dip in stock price, Boston Scientific still flexed its ...

Cartesian Therapeutics Inc. followed up December’s phase IIb data with more good news regarding Descartes-08, offering 12-month efficacy and safety results that whetted Wall Street’s appetite for the ...

Pulsed field ablation using Boston Scientific Corp.’s Farapulse system was non-inferior and even superior, slightly, to Medtronic plc’s Artic Front Advance cardiac cryoablation system in treating ...

Boston Scientific’s pulsed field ablation catheter, Farapulse, was noninferior to Medtronic’s Arctic Front cryoballoon in a randomized trial, researchers found in a study published in The New ...

The Farapulse system in full with the Farawave ablation catheter, Farastar ablation generator and Faradrive steerable sheath. [Image courtesy of Boston Scientific] Boston Scientific (NYSE ...

Abbott has trailed medtech competitors in bringing a PFA device to market, but now plans to accelerate its European rollout in the second half of this year, after beginning with EU physicians familiar ...